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Target Ovarian Cancer Program (TOCP):  
Systematic identification of high-risk women 
for ovarian cancer prevention 
A 
Ovarian cancer is the 5th leading cause of cancer-related death in Canadian women and is the most lethal cancer of the female 
reproductive tract 1. 1 in 5 women with the most common form of ovarian cancer, high-grade serous carcinoma (HGSC), have 
an inherited mutation in the BRCA1 or BRCA2 genes 2−3. Due to the strong link between BRCA1/2 and HGSC, the Ontario 
Ministry of Health and Long-Term Care released recommendations in 2001 that made all women with serous epithelial ovarian 
cancer eligible for BRCA1/2 testing. In the following decade only ~20% of eligible patients were referred
 4
, resulting in up to 
2000 women in Ontario with inherited BRCA1/2 mutations who have not been identified and are unaware of their high risk for 
deadly ovarian cancer. The purpose of this initiative is to identify these women who carry BRCA1/2 mutations and other risk 
genes through genetic testing and provide the opportunity to prevent ovarian cancer by risk-reducing  surgery 5−7.  
TOCP website - www.preventovariancancer.ca 
